Detalles de la búsqueda
1.
Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer.
Future Oncol
; 16(12): 749-762, 2020 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-32228198
2.
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Lancet
; 389(10066): 255-265, 2017 01 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-27979383
3.
Avelumab Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With High-Expression Programmed Death-Ligand 1-Positive Metastatic NSCLC: Primary Analysis From the Phase 3 JAVELIN Lung 100 Trial.
J Thorac Oncol
; 19(2): 297-313, 2024 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37748693
4.
Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial.
J Thorac Oncol
; 18(12): 1731-1742, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37597750
5.
nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+).
Front Oncol
; 10: 569715, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33643895
6.
A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer.
Clin Lung Cancer
; 18(6): 615-625.e8, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28601388
Resultados
1 -
6
de 6
1
Próxima >
>>